[
  {
    "ts": null,
    "headline": "PFE's Hympavzi Phase III Hemophilia Study With Inhibitors Meets Goal",
    "summary": "Pfizer's Hympavzi meets key phase III goals, demonstrating a significant reduction in bleeding in hemophilia patients with inhibitors.",
    "url": "https://finnhub.io/api/news?id=63dccf86936188e7c046cd6eac091e8d6a3efa0766113c3cc809ae662a33a372",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751036280,
      "headline": "PFE's Hympavzi Phase III Hemophilia Study With Inhibitors Meets Goal",
      "id": 135596677,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer's Hympavzi meets key phase III goals, demonstrating a significant reduction in bleeding in hemophilia patients with inhibitors.",
      "url": "https://finnhub.io/api/news?id=63dccf86936188e7c046cd6eac091e8d6a3efa0766113c3cc809ae662a33a372"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer reports positive results from Phase III BAISIS trial for haemophilia",
    "summary": "The trial aims to assess the therapy’s safety and efficacy in participants aged between 12 and 75 years old.",
    "url": "https://finnhub.io/api/news?id=90d0cb136e796537b59144c2f227b611b3b56d17cb92ae729c75181a777bca8b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751016911,
      "headline": "Pfizer reports positive results from Phase III BAISIS trial for haemophilia",
      "id": 135596678,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The trial aims to assess the therapy’s safety and efficacy in participants aged between 12 and 75 years old.",
      "url": "https://finnhub.io/api/news?id=90d0cb136e796537b59144c2f227b611b3b56d17cb92ae729c75181a777bca8b"
    }
  },
  {
    "ts": null,
    "headline": "Sickle Cell Disease Treatment Market Analysis and Forecast, 2025-2035 | Intensifying Competition as Key Players Advance Gene and Novel Therapies",
    "summary": "The global sickle cell disease treatment market is poised for significant growth, driven by the increasing prevalence of the disease and the demand for effective treatments. North America, led by the U.S., dominates the market with strong healthcare infrastructure, government support, and research innovations. In Asia-Pacific, countries like China and India are experiencing rapid market growth due to rising healthcare expenditure and increased awareness. Europe also contributes significantly, su",
    "url": "https://finnhub.io/api/news?id=2e76e3692da6d08e1ef6925e156aef3543b943f2ab86f7ff300efa08d44c97e3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751012520,
      "headline": "Sickle Cell Disease Treatment Market Analysis and Forecast, 2025-2035 | Intensifying Competition as Key Players Advance Gene and Novel Therapies",
      "id": 135584785,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The global sickle cell disease treatment market is poised for significant growth, driven by the increasing prevalence of the disease and the demand for effective treatments. North America, led by the U.S., dominates the market with strong healthcare infrastructure, government support, and research innovations. In Asia-Pacific, countries like China and India are experiencing rapid market growth due to rising healthcare expenditure and increased awareness. Europe also contributes significantly, su",
      "url": "https://finnhub.io/api/news?id=2e76e3692da6d08e1ef6925e156aef3543b943f2ab86f7ff300efa08d44c97e3"
    }
  }
]